Certara (CERT) Projected to Release Quarterly Earnings on Thursday

Key Points

• Certara is expected to report Q3 2026 results before market open on November 5, with analysts forecasting earnings of $0.0866 per share and revenue of $91.98 million.
• The company’s previous quarter fell short of expectations, reporting $0.08 EPS versus $0.09 expected and $93.27 million in revenue versus $98.09 million; revenue declined 10.8% year over year.
• Analyst sentiment is mixed, with an overall “Hold” rating and an average price target of $9.18, while Certara’s shares recently opened at $11.48 after trading between $4.45 and $12.29 over the past year.

Certara (NASDAQ:CERT - Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Certara to announce earnings of $0.0866 per share and revenue of $91.98 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%. Certara's revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.07 EPS. On average, analysts expect Certara to post $0.22 EPS for the current fiscal year and $0.28 EPS for the next fiscal year.

Certara Stock Performance

CERT opened at $11.48 on Thursday. The company has a quick ratio of 2.55, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. The stock's 50 day moving average price is $8.91 and its two-hundred day moving average price is $7.28. The firm has a market capitalization of $1.75 billion, a P/E ratio of -25.51 and a beta of 1.42. Certara has a 12-month low of $4.45 and a 12-month high of $12.29.

Wall Street Analyst Weigh In

CERT has been the subject of several research reports. TD Cowen increased their price objective on Certara from $9.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, October 13th. Barclays boosted their target price on shares of Certara from $7.50 to $9.00 and gave the stock an "equal weight" rating in a research report on Wednesday, October 7th. Weiss Ratings downgraded shares of Certara from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday, October 8th. KeyCorp raised their price target on shares of Certara from $9.00 to $12.00 and gave the stock an "overweight" rating in a research report on Friday, October 16th. Finally, UBS Group lowered shares of Certara from a "buy" rating to a "neutral" rating and set a $10.00 price target on the stock. in a research report on Wednesday, September 30th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $9.18.

Certara Company Profile

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.